A citation-based method for searching scientific literature

Enrica Di Martino, Alessio Provenzani, Patrizio Vitulo, Piera Polidori. Ann Pharmacother 2021
Times Cited: 4







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
75

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
50

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
430
50

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
641
50

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
348
50

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
210
50

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
50

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Hee-Young Yoon, Sojung Park, Dong Soon Kim, Jin Woo Song. Respir Res 2018
35
50

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
50

The natural history of progressive fibrosing interstitial lung diseases.
Martin Kolb, Martina Vašáková. Respir Res 2019
66
25

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.
Motoyasu Kato, Shinichi Sasaki, Takahiro Nakamura, Kana Kurokawa, Tomoko Yamada, Yusuke Ochi, Hiroaki Ihara, Fumiyuki Takahashi, Kazuhisa Takahashi. Sci Rep 2019
11
25

Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Paola Rogliani, Luigino Calzetta, Francesco Cavalli, Maria Gabriella Matera, Mario Cazzola. Pulm Pharmacol Ther 2016
75
25

Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.
Nora M Thoua, Catey Bunce, Geraldine Brough, Alastair Forbes, Anton V Emmanuel, Christopher P Denton. Rheumatology (Oxford) 2010
51
25

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.
Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B Münster, Marjukka Myllärniemi, Claudia Ravaglia,[...]. Respiration 2019
21
25

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Tamera Corte, Francesco Bonella, Bruno Crestani, Maurits G Demedts, Luca Richeldi, Carl Coeck, Katy Pelling, Manuel Quaresma, Joseph A Lasky. Respir Res 2015
72
25

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.
Imre Noth, David Oelberg, Manika Kaul, Craig S Conoscenti, Ganesh Raghu. Eur Respir J 2018
19
25

Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
Aristeidis Skandamis, Chara Kani, Sophia L Markantonis, Kyriakos Souliotis. J Drug Assess 2019
11
25

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Lisa Lancaster, Bruno Crestani, Paul Hernandez, Yoshikazu Inoue, Daniel Wachtlin, Lazaro Loaiza, Manuel Quaresma, Susanne Stowasser, Luca Richeldi. BMJ Open Respir Res 2019
52
25


Gastrointestinal manifestations of mixed connective tissue disease.
J B Marshall, J M Kretschmar, D C Gerhardt, D H Winship, D Winn, E L Treadwell, G C Sharp. Gastroenterology 1990
63
25

Gastrointestinal Manifestations of Systemic Sclerosis.
Isabel M McFarlane, Manjeet S Bhamra, Alexandra Kreps, Sadat Iqbal, Firas Al-Ani, Carla Saladini-Aponte, Christon Grant, Soberjot Singh, Khalid Awwal, Kristaq Koci,[...]. Rheumatology (Sunnyvale) 2018
30
25

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Bram Rochwerg, Binod Neupane, Yuan Zhang, Carlos Cuello Garcia, Ganesh Raghu, Luca Richeldi, Jan Brozek, Joseph Beyene, Holger Schünemann. BMC Med 2016
52
25

Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review.
Sabrina Carvajalino, Carla Reigada, Miriam J Johnson, Mendwas Dzingina, Sabrina Bajwah. BMC Pulm Med 2018
31
25

Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis.
Gian Luca Erre, Marco Sebastiani, Maria Antonietta Fenu, Angelo Zinellu, Alberto Floris, Lorenzo Cavagna, Elisabetta Renzoni, Andreina Manfredi, Giuseppe Passiu, Richard John Woodman,[...]. J Clin Med 2020
7
25

Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Emma Loveman, Vicky R Copley, David A Scott, Jill L Colquitt, Andrew J Clegg, Katherine M A O'Reilly. BMC Pulm Med 2015
38
25

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
404
25

Adverse events during placebo vs. no drug administration--results of a randomised interventional trial in 160 volunteers.
Frank Erbguth, Angelika Hamacher-Erbguth, Uwe Fuhr, Fritz Sörgel. Eur J Clin Pharmacol 2015
1
100

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. Ann Intern Med 2009
25

Placebo and Nocebo Effects.
Luana Colloca, Arthur J Barsky. N Engl J Med 2020
103
25

Mechanisms of TKI-induced diarrhea in cancer patients.
Joanne M Bowen. Curr Opin Support Palliat Care 2013
35
25

Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study.
Katerina Antoniou, Katerina Markopoulou, Argyrios Tzouvelekis, Athina Trachalaki, Eirini Vasarmidi, Jiannis Organtzis, Vasilios Tzilas, Evangelos Bouros, Georgia Kounti, Christina Rampiadou,[...]. ERJ Open Res 2020
12
25

Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials.
Wim Wuyts, Danielle Antin-Ozerkis, J Terrill Huggins, Peter P LaCamera, Paolo Spagnolo, Martina Vašáková, Marlies S Wijsenbeek, Boris Polman, Klaus-Uwe Kirchgaessler, Mary Beth Scholand. Respir Med 2019
2
50

Meta-analysis in clinical trials.
R DerSimonian, N Laird. Control Clin Trials 1986
25

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
Arata Azuma, Hiroyuki Taniguchi, Yoshikazu Inoue, Yasuhiro Kondoh, Takashi Ogura, Sakae Homma, Tsuyoshi Fujimoto, Wataru Sakamoto, Yukihiko Sugiyama, Toshihiro Nukiwa. Respirology 2017
26
25

Natural history of idiopathic pulmonary fibrosis.
Hyun Joo Kim, David Perlman, Rade Tomic. Respir Med 2015
74
25

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
25

Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.
Vibha N Lama, Kevin R Flaherty, Galen B Toews, Thomas V Colby, William D Travis, Qi Long, Susan Murray, Ella A Kazerooni, Barry H Gross, Joseph P Lynch,[...]. Am J Respir Crit Care Med 2003
322
25


Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis.
Baruch Vainshelboim, Jose Oliveira, Liora Yehoshua, Israela Weiss, Benjamin Daniel Fox, Oren Fruchter, Mordechai Reuven Kramer. Respiration 2014
72
25

Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia.
Suzana Erico Tanni, Simone Alves Vale, Paula S Lopes, Marcelo M Guiotoko, Ilda Godoy, Irma Godoy. J Bras Pneumol 2007
11
25

A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation.
Hiroshi Date, Yasushi Tanimoto, Keiji Goto, Ichiro Yamadori, Motoi Aoe, Yoshifumi Sano, Nobuyoshi Shimizu. Chest 2005
8
25

Honeycomb lung: history and current concepts.
Hiroaki Arakawa, Koichi Honma. AJR Am J Roentgenol 2011
30
25

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse. Respiration 2016
40
25

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Ganesh Raghu, Kevin K Brown, Harold R Collard, Vincent Cottin, Kevin F Gibson, Robert J Kaner, David J Lederer, Fernando J Martinez, Paul W Noble, Jin Woo Song,[...]. Lancet Respir Med 2017
119
25

Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Susumu Sakamoto, Kensuke Kataoka, Yasuhiro Kondoh, Motoyasu Kato, Masaki Okamoto, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Kazuhiro Yatera, Yoshinori Tanino,[...]. Eur Respir J 2021
7
25


Single Versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis in the Lung Allocation Score Era.
John R Spratt, Rade Tomic, Roland Z Brown, Kyle Rudser, Gabriel Loor, Marshall Hertz, Sara Shumway, Rosemary F Kelly. J Surg Res 2019
8
25

Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
Michael T Durheim, Harold R Collard, Rhonda S Roberts, Kevin K Brown, Kevin R Flaherty, Talmadge E King, Scott M Palmer, Ganesh Raghu, Laurie D Snyder, Kevin J Anstrom,[...]. Lancet Respir Med 2015
45
25

Gastroesophageal reflux disease and idiopathic pulmonary fibrosis.
Yevgenia Y Pashinsky, Barry W Jaffin, Virginia R Litle. Mt Sinai J Med 2009
13
25

Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.
Raphael Borie, Caroline Kannengiesser, Sandrine Hirschi, Jérôme Le Pavec, Hervé Mal, Emmanuel Bergot, Stéphane Jouneau, Jean-Marc Naccache, Patrick Revy, David Boutboul,[...]. J Heart Lung Transplant 2015
63
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.